Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Venous Thromboembolism 3Lung Neoplasms 2Venous Thrombosis 1Pulmonary Embolism 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Sorafenib 4Blood Specimen Collection 4lenvatinib 3sintilimab 2halofantrine 2camrelizumab 2Liver Transplantation 2Antibodies 2trametinib 1toripalimab 1titanium silicide 1tislelizumab 1pembrolizumab 1ledipasvir, sofosbuvir drug combination 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1bavituximab 1avatrombopag 1aumolertinib 1atezolizumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Sofosbuvir 1Shadowing Technique, Histology 1Ropivacaine 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Diseases × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡